These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14511643)

  • 1. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells.
    Pala L; Mannucci E; Pezzatini A; Ciani S; Sardi J; Raimondi L; Ognibene A; Cappadona A; Vannelli BG; Rotella CM
    Biochem Biophys Res Commun; 2003 Oct; 310(1):28-31. PubMed ID: 14511643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
    Kieffer TJ; McIntosh CH; Pederson RA
    Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells.
    Pala L; Pezzatini A; Dicembrini I; Ciani S; Gelmini S; Vannelli BG; Cresci B; Mannucci E; Rotella CM
    Acta Diabetol; 2012 Dec; 49 Suppl 1():S59-63. PubMed ID: 20455069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
    Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
    Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
    Holst JJ; Deacon CF
    Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury.
    Higashijima Y; Tanaka T; Yamaguchi J; Tanaka S; Nangaku M
    Am J Physiol Renal Physiol; 2015 Apr; 308(8):F878-87. PubMed ID: 25656369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
    Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
    Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.
    Hansen L; Deacon CF; Orskov C; Holst JJ
    Endocrinology; 1999 Nov; 140(11):5356-63. PubMed ID: 10537167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
    Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
    Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice.
    Nonogaki K; Kaji T
    Diabetes Metab; 2015 Nov; 41(5):425-8. PubMed ID: 26234524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
    Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
    Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential.
    Green BD; Irwin N; Flatt PR
    Peptides; 2006 Jun; 27(6):1349-58. PubMed ID: 16406202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.
    Balkan B; Kwasnik L; Miserendino R; Holst JJ; Li X
    Diabetologia; 1999 Nov; 42(11):1324-31. PubMed ID: 10550416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
    Sakai M; Uchii M; Myojo K; Kitayama T; Kunori S
    Eur J Pharmacol; 2015 Aug; 761():109-15. PubMed ID: 25936515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions.
    Pala L; Ciani S; Dicembrini I; Bardini G; Cresci B; Pezzatini A; Giannini S; Mannucci E; Rotella CM
    Diabet Med; 2010 Jun; 27(6):691-5. PubMed ID: 20546289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy.
    Hasan AA; Hocher B
    J Mol Endocrinol; 2017 Jul; 59(1):R1-R10. PubMed ID: 28420715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion.
    McKillop AM; Stevenson CL; Moran BM; Abdel-Wahab YHA; Flatt PR
    Peptides; 2018 Feb; 100():165-172. PubMed ID: 29412816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.